切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2016, Vol. 05 ›› Issue (04) : 328 -332. doi: 10.3877/cma.j.issn.2095-3224.2016.04.010

所属专题: 文献

论著

RhoGDI2蛋白的高表达与结直肠癌侵袭和转移的相关性分析
鲁守堂1, 吴穗芳2, 金美玲3, 王启龙3, 甄亚男3, 石会勇3, 李成军3, 徐忠法3,()   
  1. 1. 250200 济南大学山东省医学科学院医学与生命科学学院;250031 山东省医学科学院附属医院胃肠外科
    2. 250117 山东省肿瘤医院肿瘤内科
    3. 250031 山东省医学科学院附属医院胃肠外科
  • 收稿日期:2016-04-13 出版日期:2016-08-25
  • 通信作者: 徐忠法
  • 基金资助:
    山东省医学科学院青年基金资助项目(No.2012-35)

Overexpression of RhoGDI2 protein correlates with tumor invasion and metastasis in colorectal cancer

Shoutang Lu1, Suifang Wu2, Meiling Jin3, Qilong Wang3, Yanan Zhen3, Huiyong Shi3, Chengjun Li3, Zhongfa Xu3,()   

  1. 1. School of Medicine and life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan 250200, China; Department of Gastrointestinal Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan 250031, China
    2. Department of Medical oncology, Shandong Tumor Hospital, Shandong 250117, China
    3. Department of Gastrointestinal Surgery, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan 250031, China
  • Received:2016-04-13 Published:2016-08-25
  • Corresponding author: Zhongfa Xu
  • About author:
    Corresponding author: Xu Zhongfa, Email:
引用本文:

鲁守堂, 吴穗芳, 金美玲, 王启龙, 甄亚男, 石会勇, 李成军, 徐忠法. RhoGDI2蛋白的高表达与结直肠癌侵袭和转移的相关性分析[J]. 中华结直肠疾病电子杂志, 2016, 05(04): 328-332.

Shoutang Lu, Suifang Wu, Meiling Jin, Qilong Wang, Yanan Zhen, Huiyong Shi, Chengjun Li, Zhongfa Xu. Overexpression of RhoGDI2 protein correlates with tumor invasion and metastasis in colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(04): 328-332.

目的

通过检测RhoGTP酶解离抑制因子2(RhoGTPase dissociation inhibitor 2,RhoGDI2)在结直肠癌和癌旁组织中的表达并结合临床病理特点进行分析,探讨RhoGDI2的蛋白表达水平与结直肠癌侵袭转移的关系及在肿瘤发生发展中的作用。

方法

选取山东省医学科学院附属医院2012年07月至2014年07月采取手术切除的153例结直肠癌病例,采用免疫组织化学检测153例肿瘤组织标本和癌旁标本中RhoGDI2蛋白的表达水平。

结果

RhoGDI2蛋白在结肠癌组织中呈阳性表达,且主要在胞浆中表达;但在癌旁正常组织中无阳性表达(57.5% vs 0.00%)。结直肠癌组织中RhoGDI2蛋白的表达在低分化组显著高于高中分化组(χ2=2.090,P<0.05)。RhoGDI2的阳性表达与结直肠肿瘤的大小呈正相关,肿瘤越大阳性表达率越高(χ2=4.293,P<0.05),并随着肿瘤浸润深度阳性表达率增加(χ2=1.711,P<0.05),其在有淋巴结转移者表达显著高于无淋巴结转移者(χ2=5.925,P<0.05)、有远处转移者显著高于无远处转移者(χ2=5.519,P<0.05),并且与临床分期密切相关,分期较晚的显著高于分期较早的(χ2=5.683,P<0.05)。RhoGDI2在结直肠癌中的阳性表达与年龄(<60 years vs ≥60 years)(χ2=0.054,P>0.05),性别(χ2=0.037,P>0.05)无相关性。

结论

RhoGDI2在结直肠癌中高表达,并且与结直肠癌的局部侵袭和远处转移呈正相关。RhoGDI2可能在结直肠的发生发展和侵袭转移过程中起着重要的作用。

Objective

To detect the expression of Rho GDP dissociation inhibitor 2 (RhoGDI2) and analyze the function of RhoGDI2 in the colorectal cancer. To discuss the role of RhoGDI2 in the developmetal process of colorectal cancer.

Methods

Immunohistochemistry was used to detect RhoGDI2 protein in 153 cases of colorectal cancer and adjacent tissue specimens.

Results

Specimens from 153 cases of colorectal cancer were selected from Affiliated Hospital of Shandong Academy of Medical Sciences between July 2012 and July 2014. RhoGDI2 was expressed mainly in colorectal cancer, mainly in the cytoplasm. The positive rate of RhoGDI2 protien expression was significantly higher in cancer tissue than in normal colorectal tissue (57.5 % vs 0.00%). RhoGDI2 expression in colorectal cancer tissue with the low differentiation group was significantly higher than in the high and moderate differentiation group. The expression of RhoGDI2 protein in colorectal cancer was significantly correlated with tumor size (χ2=4.293, P<0.05), grade of differentiation (χ2=2.090, P<0.05), depth of invasion (χ2=1.711, P<0.05), lymph node metastasis (χ2=5.925, P<0.05), distant metastasis (χ2=5.519, P<0.05), and clinical stage (χ2=5.683, P<0.05). RhoGDI2 expression in colorectal cancer was no correlated with gender (χ2=0.037, P>0.05)、age (<60 years vs≥60 years) (χ2=0.054, P>0.05).

Conclusions

RhoGDI2 expression was positively correlated with the invasion and metastasis of colorectal cancer, and RhoGDI2 may play an important role in the occurrence and development of colorectal cancer.

表1 RhoGDI2蛋白表达与结直肠癌临床病理特点的关系表
图1 RhoGDI2蛋白在正常组织和癌组织中的表达。A:正常组织表达阴性(×200);B:高分化腺癌RhoGDI2表达阳性(×200);C:中分化腺癌表达阳性(×200);D:低分化腺癌表达阳性(×200)
[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016, 66(2):115-132.
[2]
Takanori Ochiai, Taiki Masuda, Masayuki Yagi, et al. Successful combination therapy of radical liver resection with 5-Fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case[J].International Surgery, 2012, 97(1):6-13.
[3]
Nobes CD, Hall A. Rho, rac and cdc42 GTPase:regulators of actin structures,cell adhesion and motility[J]. Biochem Soc Trans, 1995, 23(3):456-459.
[4]
Aznar S, Lacal JC. Rho signals to ell growth and apoptosis[J]. Cancer Lett, 2001, 165(1):1-10.
[5]
Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of family GTPase activities[J]. Biochem J, 2005, 390(Pt1):1-9.
[6]
Seraj MJ, Harding MA, Gildea JJ, et al. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential inlineage related human bladder cancer cell lines[J]. Clin Exp Metastasis, 2000, 18(6):519-525.
[7]
Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer[J]. Clin Cancer Res, 2004, 10(11):3800-3806.
[8]
Huiyan N, Hui L, Can X, et al. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis[J]. Oncology Reports, 2010, 24(2):465-471.
[9]
Liya M, Gaixiang X, Anna S, et al. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma[J]. British Journal of Haematology, 2007, 139(2):217-223.
[10]
鲁守堂,杨建树,李成军,等. RhoGDI2蛋白的高表达促进胃癌的侵袭和转移[J].世界华人消化杂志, 2015(13):2064-2070.
[11]
Hee Jun C, Kyoung Eun B, Sun-Mi P, et al. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer[J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 2009, 15(8):2612-2619.
[12]
Bsc X L, Bsc J W, Zhang X, et al. Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma[J]. Annals of Surgical Oncology, 2012, 19(1):145-153.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 付佳, 肖海敏, 武曦, 冯涛, 师帅. 年龄校正查尔森合并症指数对腹腔镜结直肠癌围手术期并发症的预测价值[J]. 中华普通外科学文献(电子版), 2023, 17(05): 336-341.
[5] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[6] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[7] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[8] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[9] 常剑, 邱峰, 毛郁琪. 摄食抑制因子-1与腹腔镜结直肠癌根治术后肝转移的关系分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 502-505.
[10] 王晓燕, 肖佑, 肖戈, 王真权. 老年结直肠癌肺转移CT特征及高危因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 506-509.
[11] 康海, 谭武宾, 周松, 毛正, 米泽振, 李铁求. 膀胱癌根治术后阴茎转移一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 523-525.
[12] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[13] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[14] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[15] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
阅读次数
全文


摘要